AstraZeneca’s (AZN) Overweight Rating Reiterated at JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reaffirmed by JPMorgan Chase & Co. in a research report issued to clients and investors on Friday,Digital Look reports. They currently have a £140 ($176.26) price objective on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 37.20% from the company’s current price.

Several other equities research analysts also recently issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £110 ($138.49) price target on shares of AstraZeneca in a report on Tuesday, September 3rd. Berenberg Bank reiterated a “buy” rating and set a £150 ($188.85) price objective on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of £104.12 ($131.09).

AstraZeneca Trading Up 1.4 %

LON:AZN opened at £102.04 ($128.47) on Friday. The firm has a market capitalization of £158.16 billion, a price-to-earnings ratio of 3,232.38, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 1-year low of GBX 9,461 ($119.11) and a 1-year high of £133.88 ($168.55). The business’s 50-day moving average price is £113.96 and its two-hundred day moving average price is £120.77. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

Insider Transactions at AstraZeneca

In related news, insider Tony Mok acquired 1,500 shares of the stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of £126.80 ($159.64) per share, with a total value of £190,200 ($239,456.12). Also, insider Michel Demare bought 2,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were purchased at an average cost of GBX 118 ($1.49) per share, for a total transaction of £2,360 ($2,971.17). Insiders purchased a total of 23,500 shares of company stock valued at $223,316,000 in the last quarter. 0.04% of the stock is currently owned by company insiders.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.